TREVI THERAPEUTICS INC

Company Overview

Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical focused on Haduvio (oral nalbuphine ER), a kappa-agonist/mu-antagonist being developed to treat chronic cough in IPF, non-IPF ILD and refractory chronic cough. The company has completed positive Phase 2a studies (CANAL, RIVER), announced statistically significant Phase 2b CORAL topline results in June 2025, and is running supportive studies (TIDAL) while preparing for Phase 3 and regulatory meetings. Trevi is R&D-centric with no product revenue, outsources all manufacturing, holds licensed core IP from Endo/Penwest, and had ~26 employees; its operations and valuation are highly milestone-driven and dependent on clinical outcomes, third‑party supply continuity and future financing. Management currently reports a cash runway well into 2029 after a large June 2025 equity raise but will still require additional capital to complete pivotal programs and commercial launch.

Executive Compensation Practices

Given Trevi’s clinical-stage biotech profile and the filing disclosures, compensation is likely weighted toward equity-based incentives (stock options, RSUs, performance‑based awards) to conserve cash while aligning executives with long‑term clinical and regulatory milestones. The 2024–2025 MD&A explicitly notes higher stock‑based compensation and increased headcount, consistent with ramping R&D activity — pay packages will therefore emphasize milestone triggers (trial enrollment/readouts, FDA meetings, Phase 3 starts) and multi‑year retention provisions to retain small specialized management and clinical teams. For future commercialization planning, senior commercial hires may receive sales‑linked bonuses or long‑term incentive packages tied to launch metrics and reimbursement outcomes; licensing/royalty obligations to licensors could also produce milestone ceilings or clawbacks embedded in executive agreements. Expect relatively modest cash salaries versus larger equity upside, with SOX/404(b) preparedness and governance upgrades potentially driving incremental G&A-related compensation and consultant pay.

Insider Trading Considerations

Insider trading activity at Trevi should be viewed through the lens of frequent, high-impact clinical catalysts (CORAL topline, TIDAL, FDA EOP2 meeting, Phase 3 initiation) and periodic financings; insiders commonly trade around these binary events, and trading windows/blackouts will be strict in the run‑up to trial readouts and regulatory interactions. Because the company relies heavily on equity financing and has recently increased stock‑based awards, watch for Form 4 patterns such as option exercises followed by immediate sales (tax or liquidity-driven), plus any 10b5‑1 plan disclosures tied to scheduled selling. Material nonpublic information risks are heightened given opioid‑class regulatory scrutiny (abuse‑potential data, scheduling risk), so expect conservative internal policies and potential externally imposed trading restrictions following HAP or regulatory submissions. For traders/researchers, insider purchases (rare in loss-making biotechs) would be a stronger confidence signal than routine option exercises or post-grant sales, while clustered sales by multiple insiders near financings or after dilutive offerings can signal liquidity needs rather than loss of clinical confidence.